Future Directions for Treating Stage 1B, Grade 3 Endometrial Cancer

David Barrington, MD, obstetrics & gynecology specialist at Ohio State University Comprehensive Cancer Center, discusses the next steps for oncologists treating patients with stage 1B, grade 3 endometrial cancer.

The future of this space will rely heavily on evaluating results from various clinical trials to provide more guidance and recommendations for treatment options. Particularly, Barrington notes that immunotherapy will continue to play a large role in this setting when used alone and in combination with other treatments.

In addition, emerging clinical and preclinical data examining immunotherapy checkpoint inhibitors, molecular therapy, and immunotherapy, aim to further change the landscape for these early stage cancers.

Transcription:

0:08 | We're starting to see immunotherapy play a larger and larger role in the recurrent setting in the ongoing clinical trials looking at immunotherapy in combination with traditional cytotoxic chemotherapy, comparing the 2 in combination to traditional cytotoxic chemotherapy. As we see it, I think we're going to continue to see immunotherapy gain traction, either in combination treatment or as a standalone therapy.